Polish study on MRI-ultrasound for targeted prostate biopsy wins CEM award

November 12, 2013

Using Magnetic Resonance Imaging-Ultrasound (MRIUS)- guided prostate biopsy has high sensitivity to detect prostate abnormalities compared with transrectal ultrasonography (TRUS biopsy) of MRI positive findings.

The study won the first prize from Karl Storz for best poster at the EAU 13th Central European Meeting (CEM) held from October 4 to 6, 2013 in Prague, Czech Republic.

"The systematic 12-core transrectal ultrasound guided biopsy (TRUS biopsy) which is currently considered the standard of care for the diagnosis of cancer (PCa), misses many small, non-palpable and ultrasound invisible lesions," said presenting author Anna Katarzyna Czech of the Dept. of Urology, Jagiellonian University in Krakow, Poland.

Although the new imaging modalities, including MRI, have improved the rate of tissue abnormality detection, Czech said these procedures are time consuming and uncomfortable for a patient which limits their use. "However, by fusing MRI with TRUS images it became possible for the urologist to perform the MRI guided TRUS biopsies in the office setting," she added.

In their study, Czech and colleagues used the real-time fusion of TRUS images with previously recorded MR images (MRIUS), based on linear interpolation of pixels. Eighty men, who had prostate lesions detected exclusively in the transrectal prostate magnetic resonance imaging, were included in the study. All men were randomised into two groups (40 patients each) and underwent TRUS guided biopsy.

In group I, TRUS biopsies of MRI identified lesions were performed, while in group II: biopsies of the lesions visualised in MRI were performed using MRIUS method which allowed for the real-time fusion of TRUS images with previously recorded MR images.

Histopathological examination of TRUS guided of MRI identified lesions was positive for prostate cancer in 8 cases, for ASAP and HGPIN in 3 and for chronic prostatitis in 5. No microscopic pathologies were identified in 24 patients. In group II, there were 17 cases of prostate cancer, 8 of ASAP and HGPIN, and 8 of chronic prostatitis found. In 8 out of 40 men, histopathological examination identified no abnormalities.

In their results, the researchers said MRIUS guided prostate biopsy yielded 22.5%, 10% and 7.5% more prostate cancer, ASAP and HGPIN and chronic prostatitis cases, respectively compared with TRUS biopsies of the MRI identified lesions.

The sensitivity to identify microscopically confirmed prostate abnormalities was 40% (95% CI: 24.9-56.7) with TRUS guided prostate biopsy of MRI identified lesions and 80% (95% CI: 64.4-90.9) with MRIUS method. This difference was statistically significant (p=0.001).

"Fusion technology guided biopsy yielded 42.5% more prostate abnormalities than the TRUS biopsy of MRI positive lesions. Moreover, MRIUS targeted biopsies were sufficient in all PCa cases to determine their clinical significance, making the fusion technology a potential solution for the patients with clinical suspicion of ," explained Czech.

She added that further research will determine the relevance of an endorectal coil used during MRI for prostate deformation, and gland volume measurements, as well as the feasibility of MRIUS in order to detect PCa in larger prostates.

She also noted that the use of 3Tesla MRI for fusion technology, which would eliminate use of endorectal coil, needs to be investigated. Despite these limitations the authors pointed out that MRIUS guided prostate biopsy has high sensitivity to detect prostate abnormalities.

"It markedly improved ability to detect clinically significant compared with TRUS biopsy of MRI positive findings," they said.

Explore further: High-tech prostate scan may boost cancer detection

More information: Golabek T., Lipczynski W., Czech A. et al., "Value of MRI-ultrasound fusion for guidance of targeted prostate biopsy," First Prize, Best Poster, EAU 13th Central European Meeting (CEM), 4 to 6 October 2013; Prague, Czech Republic; Abstract Nr: C89.

Related Stories

High-tech prostate scan may boost cancer detection

August 16, 2013
(HealthDay)—An innovative fusion of MRI and ultrasound might be a better way to detect and assess prostate cancer, while helping men avoid unnecessary biopsies, researchers say.

Physical symptoms from prostate biopsy can cause anxiety

October 23, 2013
(HealthDay)—Problematic symptoms of prostate biopsy can lead to increased anxiety in men, even when the biopsy results are negative for cancer, according to research published online Oct. 21 in the Journal of Clinical Oncology.

MRI-guided cryoablation viable for recurrent prostate cancer

August 9, 2013
(HealthDay)—In men with recurrent prostate cancer following radiation therapy, magnetic resonance imaging (MRI)-guided focal cryoablation is feasible and seems safe, according to a study published in the August issue of ...

Prostate cancer now detectable by imaging-guided biopsy

December 10, 2012
Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.

New early detection test for prostate cancer: Mi-Prostate Score test improves on PSA for predicting cancer

September 26, 2013
More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.

6 month follow-up of patients with benign MRI-guided breast biopsies may not be necessary

May 4, 2012
Short term follow-up of patients who have had a negative (benign) MRI-guided vacuum assisted breast biopsy may not be necessary, a new study indicates.

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.